H2A Developmental Core

肝细胞癌（HCC）是一种非常常见和致命的癌症在非洲，并与艾滋病毒感染者的生活 时间越长，HCC的负担可能会增加。在先前的研究中，我们的团队确定了慢性B型肝炎感染 C病毒（HBV、HCV）、HIV和曼氏血吸虫是HCC的独立危险因素。相比 对于美国，撒哈拉以南非洲的HCC发生在更年轻和更晚期的阶段， 个月建议在马凯雷雷大学的同事之间建立东非和西非伙伴关系， 乌干达、塞内加尔的法恩大学和约翰霍普金斯大学专注于艾滋病毒和肝细胞癌 非洲的肝癌（HCC）：H2A联盟。建立在长期的合作研究，指导 在这两个国家的临床活动，我们的总体目标是减少肝癌的沉重负担， 撒哈拉非洲。我们提倡使用适当的药物治疗来研究癌症拦截策略 以中断或逆转这些导致HCC的感染的影响。我们将通过以下方式实现这一目标： 发展地方能力和进行重要的研究。H2A学者奖提供了协同 为早期非洲调查人员提供资金，用于个人职业发展活动和 利用联合会实质性资源的试点项目。学者的指定将每年交替 乌干达和塞内加尔之间的联系，以及与霍普金斯建立联系的机会，将积极 追求。我们为早期非洲调查人员提供实质性试点项目资源的方法 让他们与霍普金斯的导师配对将使投资回报最大化。最终的目标是开发 一批有才华、有资格的非洲研究人员将担任艾滋病毒和HCC研究领域的领导者。

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. The H2A Scholar Award provides synergistic funding to early-stage African investigators for both individual career development activities and a mentored pilot project utilizing the substantive Consortium resources. Designation of Scholars will alternate yearly between Uganda and Senegal and opportunities to link across countries and with Hopkins will actively be pursued. Our approach of providing early-stage African investigators with substantive pilot project resources and pairing them with a Hopkins mentor will maximize the return on investment. The ultimate goal is to develop a cadre of talented, qualified African investigators to serve as leaders in the field of HIV and HCC research.